Vince & Associates, an Altasciences Company, Awarded a $9.5-Million, Five-Year Contract for Clinical Pharmacology Studies
Overland Park, KS (November 29, 2017) — Vince & Associates Clinical Research, an Altasciences company, announced that it has been awarded a contract to carry out clinical pharmacology studies to determine the pharmacokinetics and pharmacodynamics of new medications in humans.
Vince & Associates Clinical Research, an Altasciences company, announced today that they are working with Amygdala Neurosciences Inc. to conduct a Phase 1b, proof-of-concept, dose-ranging study to evaluate the safety of the co-administration of ascending doses of ANS-6637 and ethanol in healthy male alcohol drinkers.
Vince & Associates will conduct an inpatient clinical trial on the psychological effects of an active ingredient in marijuana — cannabidiol — in support of a federal collaboration seeking to better understand the abuse potential of the substance.
Altasciences is pleased to share that they are in the final stages of completing the world’s first safety and tolerability study on a cannabis extract being developed as a new chemical entity for approval by the FDA and Health Canada as a drug.
Altasciences’ Chris Perkin Honored as One of 100 Most Inspiring Leaders in the Life Sciences Industry
Altasciences Clinical Research, one of the largest early phase Clinical Research Organizations (CROs) in North America, is pleased to announce that Chris Perkin, Chief Executive Officer, has been named one of the 100 Most Inspiring Leaders in the Life Sciences Industry by PharmaVOICE magazine for a third consecutive year — an honor bestowed on individuals recognized for the positive impact they have had on the industry through their leadership, influence and positive actions.